Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

被引：30

作者：

Le Terrier, Christophe ^{[1
,2
]}

Nordmann, Patrice ^{[1
,3
,4
,5
]}

Freret, Charlotte ^{[1
]}

Seigneur, Marion ^{[1
]}

Poirel, Laurent ^{[1
,3
]}

机构：

[1] Univ Fribourg, Fac Sci & Med, Emerging Antibiot Resistance Unit, Med & Mol Microbiol, Fribourg, Switzerland

[2] Univ Hosp Geneva, Div Intens care unit, Geneva, Switzerland

[3] Swiss Natl Reference Ctr Emerging Antibiot Resista, Fribourg, Switzerland

[4] Univ Lausanne, Lausanne, Switzerland

[5] Univ Hosp Ctr, Lausanne, Switzerland

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 07期

基金：

瑞士国家科学基金会;

关键词：

zidebactam; taniborbactam; enmetazobactam; relebactam; vaborbactam; nacubactam; susceptibility testing; beta-lactamase; avibactam;

D O I：

10.1128/aac.00339-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The impact of broad-spectrum beta-lactamases on the susceptibility to novel beta-lactamase/beta-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic antibacterial activity of zidebactam. Cefepime-taniborbactam showed excellent activity against recombinant E. coli strains, including metallo-beta-lactamase producers, whereas aztreonam-avibactam remained the best therapeutic option against class B beta-lactamase-producing P. aeruginosa.

引用

页数：9

共 21 条

[1] Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales [J].